Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2016

View Archived Issues

Vaxil Bio completes reverse takeover transaction

Microbion and Haisco enter agreement to develop and commercialize MBN-101

Onxeo acquires DNA Therapeutics, provides update on Validive development plan

CAMH and Impel NeuroPharma sign licensing agreement for neuropeptide treatment for depression

Anti-sclerostin antibody from Mereo granted U.S. orphan status for osteogenesis imperfecta

CSIR reports development of anticancer agents

Oxalate descarboxylase receives FDA orphan drug designation for pediatric hyperoxaluria

Alkem Laboratories discloses cathepsin K inhibitors

Clinical candidate GDC-0326 identified from novel, selective PI3Kalpha inhibitors

Amgen files for FDA approval of Blincyto for pediatric Ph-negative B-cell precursor ALL

GlycoMimetics announces initial clinical data from phase I trial of GMI-1271 in AML

EyeGate receives additional milestone payment for the development of EGP-437

Baxalta submits MAA for Adynovi for the treatment of hemophilia A

Nuvo Research completes reorganization

Merck Patent and Cancer Research Technology describe CDK8/cyclin C inhibitors

Johns Hopkins University patent reveals UAP inhibitors

Arromax Pharmatech divulges protein kinase inhibitors

Ixodes in SPA agreement with FDA on phase III trial of Ixogel to prevent Lyme disease

GEFs as strong prognostic markers of cancer progression

DDIT4 gene is a marker for outcomes in multiple cancer types

Otonomy launches Otiprio in U.S.

TiGenix seeks European approval for Cx-601

Phase II trial of danegaptide for cardiac reperfusion injuries does not meet primary endpoint

Interim data from phase IIb trial of VT-1161 in onychomycosis

C4X Discovery acquires Adorial and its subsidiaries

Genetic variability of SCN4A is associated with essential tremor

Cynata Therapeutics enters preliminary agreement for strategic alliance with Regience in Japan

Voclosporin receives FDA fast track designation for the treatment of lupus nephritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...